Affimed NV (AFMD) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Leerink Partners Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsDec 19, 2024 05:33 ET · Ratings
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
Moomoo NewsDec 19, 2024 05:33 ET · Ratings
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $7
Moomoo NewsDec 18, 2024 06:35 ET · Ratings
Express News | Affimed NV : H.c. Wainwright Cuts Target Price to $7 From $10
ReutersDec 18, 2024 06:17 ET
Wells Fargo Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $11
Moomoo NewsDec 17, 2024 21:31 ET · Ratings

Comments

Trytosaveabit

Dec 23, 2024 16:56

Just thinking outloud! Hehehe

$Affimed NV (AFMD.US)$ Watching for a possible DCB? Recent good data! Also just off 52Wk/ATL! And best of all i really like the DOJI today! Could be signaling exhaustion/trend reversal! Hmm? NFA

3

4

Jaguar8

Dec 9, 2024 12:35

NEWS

$Affimed NV (AFMD.US)$
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
▪️AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients
▪️AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect...

2

This_Guy

Dec 8, 2024 17:23

$Affimed NV (AFMD.US)$
🤔
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive
High overall response rate of 86% in heavily pretreated patients
Complete response rate of 55% in patients with treatment options
Well-managed safety profile with no unexpected safety signals
Successful validation of treatment in multi-center setting
Negative
None.

3

Trytosaveabit

Dec 8, 2024 15:39

Watching 12/9/24 PR / New data released 12//8

$Affimed NV (AFMD.US)$ Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%; Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc...

1

Jaguar8

Dec 8, 2024 11:00

NEWS SUNDAY 12/8

$Affimed NV (AFMD.US)$
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Sunday, 8th December at 12:00 pm
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments
The combination showed a well-managea...

1

AFMD Affimed NV

Trade Overview

Capital Trend

News

Comments